StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)

Close on Nov 17, 2026Market cap $91.09MP/E –Yield –

Earnings

Exagen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$18.40M
EPS, Q3 FY2026
-$0.25
Latest guidance
Raised
Nov 10, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Exagen's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 9, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open$18.40M–-$0.25Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 11, 2026before the open$17.30M––Release
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open$16.63M+21.8%-$0.20Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025before the open$17.20M+13.9%–Release
Q1 FY2025ended Mar 31, 2025May 5, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 11, 2025before the open$13.66M-1.1%-$0.20Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open$12.50M-6.7%–Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024before the open$15.10M+7.1%-$0.16Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open$14.40M+28.6%-$0.19Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Exagen's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$72.00M – $75.00M$70.00M – $73.00MRaisedNov 10, 2026
revenue guidanceFY2026$72.00M – $75.00M$70.00M – $73.00MRaisedAug 4, 2026

Guidance vs results

The last range Exagen gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q1 FY2024Revenue$13.00M – $13.50M$14.40MAbove range
Q3 FY2023Revenue$10.00M – $10.50M$13.40MAbove range
Q2 FY2023Revenue$10.70M – $11.20M$14.10MAbove range
Q1 FY2023Revenue$9.20M – $9.70M$11.20MAbove range

Guidance history

Every forecast Exagen put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2026revenueFY2026$72.00M – $75.00MRaised
Aug 4, 2026revenue guidanceFY2026$72.00M – $75.00MRaised
May 11, 2026revenueFY2026$70.00M – $73.00MNew
Mar 10, 2026revenueFY2026$70.00M – $73.00MNew
Nov 4, 2025full-year revenueFY2025$65.00M – $70.00MNew
Jul 29, 2025revenueFY2025$65.00M – $70.00MRaised
May 5, 2025revenueFY2025$65.00MNew
Mar 11, 2025total revenueQ1 FY2025$14.50MNew
Nov 12, 2024adjusted EBITDA lossFY2024-$12.00MLowered
Nov 12, 2024full-year revenueFY2024$55.00M – $56.00MLowered
Aug 5, 2024adjusted EBITDA lossFY2024$12.00MRaised
Aug 5, 2024revenueFY2024$57.00MRaised
May 13, 2024adjusted EBITDAFY2024-$18.00MRaised
May 13, 2024revenueFY2024$55.00MNew
Mar 18, 2024adjusted EBITDAFY2024-$20.00MNew
Mar 18, 2024revenueFY2024$54.00MNew
Mar 18, 2024revenueQ1 FY2024$13.00M – $13.50MNew
Jan 8, 2024adjusted EBITDAFY2023-$20.00MReaffirmed
Jan 8, 2024total revenueFY2023$50.00MNew
Nov 13, 2023adjusted EBITDAFY2023-$20.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Exagen filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. News
  9. News
  10. News
  11. News
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?